Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: Final 12-month, open-label results

Movement Disorders

Volumn 30, Issue 4, 2015, Pages 500-509

  Fernandez, Hubert H ^a   Standaert, David G ^b   Hauser, Robert A ^c   Lang, Anthony E ^d   Fung, Victor S C ^e   Klostermann, Fabian ^f   Lew, Mark F ^g   Odin, Per ^h   Steiger, Malcolm ⁱ   Yakupov, Eduard Z ^j   Chouinard, Sylvain ^k   Suchowersky, Oksana ^l   Dubow, Jordan ^m   Hall, Coleen M ^m   Chatamra, Krai ^m   Robieson, Weining Z ^m   Benesh, Janet A ^m   Espay, Alberto J ⁿ  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF SYDNEY   (Australia)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ Walton Center for Neurology and Neurosurgery   (United Kingdom)

^j KAZAN STATE MEDICAL UNIVERSITY   (Russian Federation)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF ALBERTA   (Canada)

^m ABBVIE INC   (United States)

ⁿ UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

more..

Author keywords

"off" time; Dyskinesia; Infusion; Levodopa carbidopa intestinal gel; Percutaneous endoscopic gastrojejunostomy

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; CARBIDOPA, LEVODOPA DRUG COMBINATION; DRUG COMBINATION; GEL; LEVODOPA;

ABDOMINAL PAIN; ADULT; ARTICLE; CACHEXIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSPHAGIA; DYSPNEA; ELECTROCARDIOGRAM; ERYTHEMA; FALLING; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; GASTROJEJUNOSTOMY TUBE; GEL; GRANULATION TISSUE; GUILLAIN BARRE SYNDROME; HIP FRACTURE; HUMAN; INCISION SITE ERYTHEMA; INSOMNIA; JEJUNOSTOMY TUBE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; MONONEUROPATHY; MONOTHERAPY; MOTOR PERFORMANCE; NAUSEA; NEURALGIA; OPEN STUDY; PARKINSON DISEASE; PERITONITIS; PNEUMONIA; PNEUMOPERITONEUM; POLYNEUROPATHY; PRIORITY JOURNAL; PROCEDURAL SITE REACTION; PROSPECTIVE STUDY; QUALITY OF LIFE; SENSORY NEUROPATHY; SUICIDE; SURGICAL INFECTION; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY TRACT INFECTION; VITAL SIGN; AGED; DRUG COMBINATION; DRUG EFFECTS; INTESTINE; MIDDLE AGED; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; INTESTINES; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84961288577     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26123     Document Type: Article

References (50)

1. Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8.
2. Hornykiewicz O. A brief history of levodopa. J Neurol 2010;257(Suppl 2):S249-S252.
3. Lundqvist C. Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat 2007;3:335-348.
4. Antonini A, Chaudhuri KR, Martinez-Martin P, Odin P. Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease. CNS Drugs 2010;24:119-129.
5. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
6. Chaudhuri KR, Rizos A, Sethi KD. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm 2013;120:1305-1320.
7. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol 1989;25:523-526.
8. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55:1-9.
9. Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord 2011;26:587-598.
10. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S97-S100.
11. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
12. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-163.
13. Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Antonini A. Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012;27:147-154.
14. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-223.
15. Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-149.
16. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson's disease. Practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-166.
17. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-1149.
18. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008;5:244-246.
19. Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-221.
20. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-1474.
21. Devos D; French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
22. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013;19:339-345.
23. Fahn S, Elton RL; UPDRS Program Members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsen CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ, USA: Macmillan; 1987:153-163.
24. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The PDQ-8: development and validation of a short-form Parkinson's Disease Questionnaire. Psychol Health 1997;12:805-814.
25. Schrag A, Selai C, Jahanshahi M, Quinn NP. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69:67-73.
26. EuroQoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
27. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
28. Hauser RA, Auinger P; Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson's disease. Mov Disord 2011;26:813-818.
29. Kostić VS, Perkmezović T, Tomić A, et al. Suicide and suicidal ideation in Parkinson's disease. J Neurol Sci 2010:289;40-43.
30. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-189.
31. Nazem S, Siderowf AD, Duda JE, et al. Suicide and death ideation in Parkinson's disease. Mov Disord 23:1573-1579.
32. Blomberg J, Lagergren J, Martin L, Mattsson F, Lagergren P. Complications after percutaneous endoscopic gastrostomy in a prospective study. Scand J Gastroenterol 2012;47:737-742.
33. Itkin M, DeLegge MH, Fang JC, McClave SA, Kundu S, d'Othee BJ, et al. Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the Society of Interventional Radiology and American Gastroenterological Association (AGA) Institute, with endorsement by Canadian Interventional Radiological Association (CIRA) and Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Gastroenterol 2011;141:742-765.
34. Epstein M, Johnson D, Hawes R, et al. Gastrointestinal safety of the levodopa-carbidopa intestinal gel delivery system in treating advanced Parkinson's patients [abstract]. Mov Disord 2013:28(Suppl 1):402.
35. Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011;77:1947-1950.
36. Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008;23:1850-1859.
37. Freeman R, Cornblath D, Anand P, et al. Incidence of peripheral neuropathy in advanced Parkinson's subjects treated with levodopa-carbidopa intestinal gel [abstract]. Mov Disord 2013;28(Suppl 1):403.
38. Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19:501-507.
39. Duodopa intestinal gel. Summary of product characteristics. Maidenhead, UK: AbbVie Limited; 2013.
40. Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease. Eur J Neurol 2012;19:1079-1085.
41. ® treatment for advanced Parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18:916-929.
42. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908.
43. Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-591.
44. Weaver FM, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009;301:63-73.
45. Martinez-Martin P, Reddy P, Antonini A, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis 2011;1:197-203.
46. Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009;119:345-348.
47. De Gaspari D, Siri C, Landi A, et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2006;77:450-453.
48. García Ruiz PJ, Sesar Ignacio A, Ares Pensado B, et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Mov Disord 2008;23:1130-1136.
49. Manson AJ, Hanagasi H, Turner K, et al. Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain 2001;124:331-340.
50. Merola A, Zibetti M, Angrisano S, Rizzi L, Lanotte M, Lopiano L. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson's disease. Mov Disord 2011;26:664-670.